When does the Entyvio patent expire?
The exact “Entyvio patent 2032” date depends on which patent family and which jurisdiction you mean (the company may have multiple patents covering different aspects of vedolizumab, such as manufacturing, formulations, or specific claims, and those can expire on different timelines). Based on the limited information available from the prompt, I can’t verify a specific, authoritative Entyvio (vedolizumab) patent expiration date in 2032.
Why do Entyvio patents have different end dates?
Patent protection for a single medicine usually isn’t one single expiration date. Different patents can expire at different times because they cover different claim types or were filed in different countries. That means “2032” might refer to:
- One specific patent within a larger portfolio
- A particular country’s filing (and its local term)
- A later-expiring secondary patent (for example, tied to a formulation/process) rather than the original compound patent
Could competitors enter before a 2032 patent date?
Even if one patent is set to expire in 2032, competitors may still face other barriers such as:
- Other still-active patents in the same portfolio
- Regulatory exclusivity (which can be separate from patents)
- Patent challenges and litigation that can delay market entry
What I need to confirm “2032” for Entyvio
If you share any of the following, I can narrow down the correct expiration timing more precisely:
- The country (US, EU, UK, Canada, etc.)
- The patent number or family identifier you’re looking at
- A link/source you saw that states “2032”
Quick clarification: is Entyvio the same as vedolizumab?
Yes. Entyvio is the brand name; the active ingredient is vedolizumab. Patent terms will apply to vedolizumab-related claims, but each patent is tied to a specific scope and jurisdiction.
Sources: none cited (the prompt did not include source material to verify an Entyvio patent expiration date).